{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:21Z","timestamp":1781639661609,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017932","name":"Western University of Health Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017932","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by impaired epidermal barrier function and immune dysregulation. Current therapies are largely symptomatic and frequently associated with adverse effects, underscoring the need for safer and more effective treatment strategies. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors of nicotinamide adenine dinucleotide (NAD\u207a) and have been reported to regulate inflammatory signaling and cellular metabolism. This study investigated the anti-inflammatory effects of NMN and NR in an in vitro model of AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Human keratinocyte HaCaT cells were stimulated with TNF-\u03b1 and IFN-\u03b3 to mimic AD-associated inflammation and pretreated with NMN or NR. Quantitative PCR analysis demonstrated that NMN significantly and dose-dependently reduced mRNA expression of IL-1\u03b2, macrophage-derived chemokine (MDC\/CCL22), CCL5 (RANTES), CCL17 (TARC), IL8, and thymic stromal lymphopoietin (TSLP). NR similarly suppressed these inflammatory mediators except IL-1\u03b2, which was not significantly reduced. Western blot analysis showed that both NMN and NR inhibited phosphorylation of p38 MAPK, whereas phosphorylation levels of AKT, ERK, NF-\u03baB, and JNK were not significantly altered. Neither compound affected cell viability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NMN and NR attenuate pro-inflammatory gene expression in cytokine-stimulated keratinocytes, primarily through inhibition of p38 MAPK signaling. NMN demonstrated broader anti-inflammatory effects than NR. These findings identify NAD\u207a precursors, particularly NMN, as potential therapeutic candidates for AD by targeting keratinocyte-mediated inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-026-11615-2","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:04:00Z","timestamp":1772611440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nicotinamide mononucleotide and nicotinamide riboside attenuate cytokine production in human keratinocytes via suppression of p38 Pathway"],"prefix":"10.1007","volume":"53","author":[{"given":"Chen","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alejandra Molina","family":"Velandia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Marecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"3","key":"11615_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.16934","volume":"180","author":"T Tsakok","year":"2019","unstructured":"Tsakok T et al (2019) Atopic dermatitis: the skin barrier and beyond. Br J Dermatol 180(3):464\u2013474","journal-title":"Br J Dermatol"},{"issue":"11","key":"11615_CR2","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00105-021-04859-5","volume":"72","author":"HA Zietze","year":"2021","unstructured":"Zietze HA et al (2021) [Epidemiology and treatment of adult patients with atopic dermatitis: Analysis of longitudinal data of the statutory health insurance scheme]. Hautarzt 72(11):963\u2013974","journal-title":"Hautarzt"},{"issue":"3\u20134","key":"11615_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0165-2427(01)00296-3","volume":"81","author":"A Hillier","year":"2001","unstructured":"Hillier A, Griffin CE (2001) The ACVD task force on canine atopic dermatitis (I): incidence and prevalence. Vet Immunol Immunopathol 81(3\u20134):147\u2013151","journal-title":"Vet Immunol Immunopathol"},{"key":"11615_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12917-015-0514-6","volume":"11","author":"T Olivry","year":"2015","unstructured":"Olivry T et al (2015) Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 11:210","journal-title":"BMC Vet Res"},{"issue":"3","key":"11615_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s10787-025-01642-z","volume":"33","author":"HM Abdel-Mageed","year":"2025","unstructured":"Abdel-Mageed HM (2025) Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights. Inflammopharmacology 33(3):1161\u20131187","journal-title":"Inflammopharmacology"},{"issue":"1","key":"11615_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cvsm.2018.08.002","volume":"49","author":"D Santoro","year":"2019","unstructured":"Santoro D (2019) Therapies in Canine Atopic Dermatitis: An Update. Vet Clin North Am Small Anim Pract 49(1):9\u201326","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"1","key":"11615_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12929-019-0527-8","volume":"26","author":"K Okabe","year":"2019","unstructured":"Okabe K et al (2019) Implications of altered NAD metabolism in metabolic disorders. J Biomed Sci 26(1):34","journal-title":"J Biomed Sci"},{"issue":"1","key":"11615_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","volume":"22","author":"C Canto","year":"2015","unstructured":"Canto C, Menzies KJ, Auwerx J (2015) NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab 22(1):31\u201353","journal-title":"Cell Metab"},{"issue":"3","key":"11615_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/ajd.12631","volume":"58","author":"DL Damian","year":"2017","unstructured":"Damian DL (2017) Nicotinamide for skin cancer chemoprevention. Australas J Dermatol 58(3):174\u2013180","journal-title":"Australas J Dermatol"},{"issue":"1","key":"11615_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/138161209787185760","volume":"15","author":"CA Benavente","year":"2009","unstructured":"Benavente CA, Jacobson MK, Jacobson EL (2009) NAD in skin: therapeutic approaches for niacin. Curr Pharm Des 15(1):29\u201338","journal-title":"Curr Pharm Des"},{"key":"11615_CR11","doi-asserted-by":"crossref","unstructured":"Surjana D, Halliday GM, Damian DL (2010) Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids 2010: 157591","DOI":"10.4061\/2010\/157591"},{"key":"11615_CR12","doi-asserted-by":"crossref","unstructured":"Poddar SK et al (2019) Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules 9(1):34","DOI":"10.3390\/biom9010034"},{"issue":"2","key":"11615_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1507\/endocrj.EJ19-0313","volume":"67","author":"J Irie","year":"2020","unstructured":"Irie J et al (2020) Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J 67(2):153\u2013160","journal-title":"Endocr J"},{"key":"11615_CR14","doi-asserted-by":"publisher","first-page":"604404","DOI":"10.3389\/fphar.2020.604404","volume":"11","author":"Y You","year":"2020","unstructured":"You Y et al (2020) Subacute Toxicity Study of Nicotinamide Mononucleotide via Oral Administration. Front Pharmacol 11:604404","journal-title":"Front Pharmacol"},{"key":"11615_CR15","doi-asserted-by":"publisher","first-page":"108812","DOI":"10.1016\/j.intimp.2022.108812","volume":"109","author":"JF Gao","year":"2022","unstructured":"Gao JF et al (2022) Nicotinamide mononucleotide ameliorates DNFB-induced atopic dermatitis-like symptoms in mice by blocking activation of ROS-mediated JAK2\/STAT5 signaling pathway. Int Immunopharmacol 109:108812","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"11615_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1089\/jmf.2024.k.0282","volume":"28","author":"HR Shin","year":"2025","unstructured":"Shin HR et al (2025) A Mixture of Nicotinamide Mononucleotide, Decursin, and l-Cysteine Lowered Senescence-Associated Markers In Vitro and Was Effective Against 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis In Vivo: An Application of Network Pharmacology. J Med Food 28(5):490\u2013500","journal-title":"J Med Food"},{"issue":"23","key":"11615_CR17","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1111\/bph.14487","volume":"175","author":"HJ An","year":"2018","unstructured":"An HJ et al (2018) Therapeutic effects of bee venom and its major component, melittin, on atopic dermatitis in vivo and in vitro. Br J Pharmacol 175(23):4310\u20134324","journal-title":"Br J Pharmacol"},{"issue":"9352","key":"11615_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0140-6736(03)12193-9","volume":"361","author":"DY Leung","year":"2003","unstructured":"Leung DY, Bieber T (2003) Atopic dermatitis. Lancet 361(9352):151\u2013160","journal-title":"Lancet"},{"issue":"1","key":"11615_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jep.2012.08.049","volume":"144","author":"YY Sung","year":"2012","unstructured":"Sung YY, Kim YS, Kim HK (2012) Illicium verum extract inhibits TNF-alpha- and IFN-gamma-induced expression of chemokines and cytokines in human keratinocytes. J Ethnopharmacol 144(1):182\u2013189","journal-title":"J Ethnopharmacol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11615-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11615-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11615-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:16:11Z","timestamp":1781637371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11615-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11615"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11615-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies on human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"459"}}